https://doi.org/10.55788/f821f6e3
Research on pathogenesis has identified that HS lesions contain B cells and plasma cells that are linked to immunoglobulin generation and complement activation [1,2]. Also, activation of BTK and spleen tyrosine kinase pathways are involved in central signal transduction.
Prof. Alexandra Kimball (Harvard Medical School, MA, USA) presented a study that investigated therapy with the selective BTK inhibitor remibrutinib for moderate-to-severe HS over 16 weeks [1]. The trial forms part of a phase 2b multicentre platform study with 5 cohorts (A to E) that assessed various agents for this indication. The rationale for cohort D, testing remibrutinib against placebo, stems from findings that point to a role of BTK activation in HS [1,2].
Cohort D included 77 participants; 33 participants were randomised to remibrutinib at either 25 mg or 100 mg twice daily over 16 weeks, 11 patients received a placebo; the pooled placebo group of all cohorts included 50 participants [1]. The primary endpoint was a simplified HS Clinical Response (HiSCR) that stands for a ≥50% reduction in abscess and nodule (AN) count with no increase in draining tunnels.
At week 16, the results revealed higher rates of participants on the BTK inhibitor achieving simplified HiSCR50 with 72.7% (25 mg) and 48.5% (100 mg) versus 34.7% (pooled placebo; see Figure). Remibrutinib in both doses was also superior to pooled placebo regarding higher HiSCR response rates: HiSCR75 was achieved by 42.4% (25 mg) and 27.3% (100 mg) versus 18.4% (pooled placebo), and HiSCR90 by 36.4% (25 mg) and 15.2% (100 mg) versus 8.2% (pooled placebo). Also, greater reductions were observed in draining tunnels and AN counts along with ameliorations in skin pain in favour of remibrutinib.
Figure: Primary study endpoint of simplified HiSCR at week 16 [1]
NRI, non-responder imputation; sHiSCR, simplified Hidradenitis Suppurativa Clinical Response.
As for safety, remibrutinib was deemed well tolerated. One grade 4 adverse event occurred in each of the remibrutinib arms, but, overall, adverse events were mainly mild to moderate.
“We are very much looking forward to how this mode-of-action will perform in the future,” Prof. Kimball concluded. Due to the novel mode-of-action, it might be possible to combine BTK inhibitors with other biologics in this indication.
Relevant readings:
- Hidradenitis suppurativa treatment with secukinumab linked to low immunogenicity (AAD 2024)
- HS: Targeting IL-1 pathway potential option after anti-TNF failure (AAD 2024)
- Kimball AB. Efficacy and safety of the oral Bruton’s tyrosine kinase inhibitor, remibrutinib, in patients with moderate to severe hidradenitis suppurativa in a randomized, phase 2, double-blind, placebo-controlled platform study. LB1, 2024 AAD Annual Meeting, 8–12 March, San Diego, USA.
- Gudjonsson JE, et al. JCI Insight. 2020;5(19):e139930.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Topical ruxolitinib shows promise in milder stages of hidradenitis suppurativa Next Article
HS: Targeting IL-1 pathway potential option after anti-TNF failure »
« Topical ruxolitinib shows promise in milder stages of hidradenitis suppurativa Next Article
HS: Targeting IL-1 pathway potential option after anti-TNF failure »
Table of Contents: AAD 2024
Featured articles
New Developments in Dermatology
Upadacitinib: A novel treatment option for vitiligo
JAK1 inhibitor meets primary endpoint in prurigo nodularis
Botanical drug solution leads to sustained hair regrowth in paediatric alopecia
SGLT2 inhibition: A possible mode-of-action for inflammatory skin diseases?
Promising first results of novel topical treatment for congenital ichthyosis
Ritlecitinib also effective in patients with total hair loss
Atopic Dermatitis and Eczema in 2024
Amlitelimab leads to a high response 28 weeks after treatment discontinuation
Delgocitinib cream: A promising treatment option for chronic hand eczema
The Latest in Psoriasis
Robust long-term efficacy of bimekizumab in psoriasis
Benefit and safety of TYK2 inhibitor ESK-001 for psoriasis in phase 2
Durable skin clearance by IL-23 blockers due to reduction of resident memory T cells
Hidradenitis Suppurativa: New Treatment Possibilities
HS: Targeting IL-1 pathway potential option after anti-TNF failure
BTK signalling as a novel target in hidradenitis suppurativa treatment
Topical ruxolitinib shows promise in milder stages of hidradenitis suppurativa
Best of the Posters
Children with atopic dermatitis may be smaller and heavier than healthy children
JAK inhibitors have similar incidence rates of long-term adverse events as traditional immunomodulators
Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years
GUIDE demonstrates: Hit hard and early in psoriasis
Hidradenitis suppurativa treatment with secukinumab linked to low immunogenicity
Related Articles
August 26, 2019
Surgeries in hidradenitis suppurativa
November 28, 2023
Skin tape stripping allows a novel precision medicine approach in HS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com